Group 1 - Domestic leading CXO companies have recently announced strong growth in their Q2 performance, attracting attention to pharmaceutical-related ETFs [1] - The Kexin Pharmaceutical ETF (588860) has shown active trading, with an average daily turnover of 22.46 million yuan since July [1] - The management fee for Kexin Pharmaceutical ETF is 0.45%, and the custody fee is 0.07%, making it the lowest among ETFs tracking the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index [1] Group 2 - The Kexin Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in the biopharmaceutical and biomedical engineering sectors [1] - As of July 29, the biopharmaceutical index covers 74.6% of the chemical pharmaceuticals and medical devices industries [1] - The introduction of the "market value + R&D" listing standard on the Science and Technology Innovation Board has significantly aided innovative pharmaceutical companies in overcoming funding bottlenecks and accelerating R&D results [1] Group 3 - Overseas CXO leaders have reported stable R&D conditions and slightly raised their annual performance guidance for 2025 [2] - The CXO industry is transitioning from a recovery phase to a performance inflection point, primarily driven by overseas revenue [2] - With a more favorable external environment and the Federal Reserve entering a rate-cutting cycle, the CXO sector is expected to experience a comprehensive recovery due to ongoing global innovation in drug development and supportive domestic policies [2]

Group 1 - The innovative drug concept remains active, with Shanghai Yizhong hitting a 20% limit up [1] - Nanxin Pharmaceutical increased by over 16% [1] - Dongcheng Pharmaceutical reached the limit up [1] Group 2 - Chenxin Pharmaceutical achieved a three-day consecutive board increase [1] - China Resources Double Crane and Asia-Pacific Pharmaceutical also saw significant gains [1]

创新药概念反复活跃，辰欣药业走出8天5板，上海谊众20cm涨停，南新制药、睿智医药涨超10%，亚 太药业、金石亚药、华润双鹤、奥锐特等涨幅靠前。 ...

报告类型 股指日评 日期 2025 年 7 月 30 日 研究员：聂嘉怡(股指) 021-60635735 niejiayi@ccb.ccbfutures.com 期货从业资格号：F03124070 研究员：何卓乔(宏观贵金属) 18665641296 hezhuoqiao@ccb.ccbfutures.com 期货从业资格号：F3008762 研究员：黄雯昕(宏观国债集运) 021-60635739 huangwenxin@ccb.ccbfutures.com 期货从业资格号：F3051589 宏观金融团队 请阅读正文后的声明 ＃summary＃ | 表1:股指期货、现货行情数据 | | --- | 资料来源：Wind，建信期货研究发展部 1.2 后市展望： 外围市场方面，中美第三轮磋商将在瑞典斯德哥尔摩举行，中方在记者会上 表示，坚决反对任何一方以牺牲中方的利益为代价达成交易，关注最终谈判结果。 国内方面，7 月 28 日，上海市经济信息化委印发 《上海市进一步扩大人工智能 应用的若干措施》，其中提到，降低智能算力使用成本，发放 6 亿元算力券，加 强算力调度平台建设，体系化支持企业研发和应用大模型，加快 ...

药明康德7月29日晚间公告称，鉴于近期公司股票价格持续上涨，基于对公司未来持续稳定发展的信心和对公司价值的认可，同时为了保障回购股份方案的顺利实施， 公司拟将2025年第一次以集中竞价交易方式回购A股股份的回购股份价格上限，由不超过90.72元/股（含）调整为不超过114.15元/股（含），本次回购方案的其他内容 不变。 创新药巨头，释放积极信号！ 7月29日晚间，药明康德公告，拟将回购股份价格上限由不超过90.72元/股（含）调整为不超过114.15元/股（含）。截至当天收盘时，药明康德股价上涨7.72%报98.69 元/股，总市值超过2800亿元。 分析人士指出，二级市场上，近期A股创新药板块持续上涨，"龙头股"药明康德上调回购价格上限，表明公司对其自身价值的高度认可，同时也向市场传递了积极信 号。 有券商表示，创新药板块景气度仍可持续，"创新+国际化"创新药产业趋势不变，始终是医药板块的核心方向。 上调 创新药板块集体爆发 7月29日，受药明康德上述超预期业绩的带动，A股创新药板块大幅上涨。截至收盘，创新药板块整体涨幅接近3%，药明康德大涨近8%，泰格医药涨近9%，众生药 业、九洲药业、辰欣药业、亚太药 ...

③北京时间7月31日凌晨，备受瞩目的美联储7月利率决议将公布。当前市场普遍押注，美联储将继续维 持现有利率水平不变，但会议声明和美联储主席鲍威尔在会后记者会上是否会释放"鸽派"信号从而为9 月可能的降息奠定基础，更加受到重视。 ②股债"跷跷板"效应再现。一方面，权益市场近期回暖明显，市场风险偏好不断提升。另一方面，资金 正在从震荡的债市中抽离。公开数据显示，7月以来，超40只债基因大额赎回而调整基金份额净值精 度。 中证网讯①7月29日，创新药主题ETF表现亮眼。今年以来，有6只ETF涨幅超100%，均为创新药主题 ETF。 ...

③北京时间7月31日凌晨，备受瞩目的美联储7月利率决议将公布。当前市场普遍押注，美联储将继续维 持现有利率水平不变，但会议声明和美联储主席鲍威尔在会后记者会上是否会释放"鸽派"信号从而为9 月可能的降息奠定基础，更加受到重视。 中证网讯 ①7月29日，创新药主题ETF表现亮眼。今年以来，有6只ETF涨幅超100%，均为创新药主题 ETF。 ②股债"跷跷板"效应再现。一方面，权益市场近期回暖明显，市场风险偏好不断提升。另一方面，资金 正在从震荡的债市中抽离。公开数据显示，7月以来，超40只债基因大额赎回而调整基金份额净值精 度。 ...

Market Overview - On July 29, the total trading volume of the Shanghai and Shenzhen stock markets reached 1.8 trillion yuan, an increase of 609 billion yuan compared to the previous trading day [1] - Sectors that saw significant gains included CRO, innovative drugs, steel, CPO, and advanced packaging, while sectors that experienced declines included insurance, pork, banking, precious metals, and agriculture [1] Top Stocks on the Dragon and Tiger List - The top three net buying stocks on the Dragon and Tiger list were Yunnan Zhiye, Zhongsheng Pharmaceutical, and Ruizhi Pharmaceutical, with net purchases of 244 million yuan, 181 million yuan, and 165 million yuan respectively [2] - The top three net selling stocks were Tibet Tianlu, Xining Special Steel, and Boyun New Materials, with net sales of 482 million yuan, 183 million yuan, and 146 million yuan respectively [3] Institutional Activity - Among stocks with institutional special seats, the top three net buying stocks were Beifang Changlong, Ruizhi Pharmaceutical, and Zhongsheng Pharmaceutical, with net purchases of 117 million yuan, 89.74 million yuan, and 83.09 million yuan respectively [4] - The top three net selling stocks with institutional special seats were Shanghai Film, Boyun New Materials, and Aiying Room, with net sales of 62.16 million yuan, 59.90 million yuan, and 45.29 million yuan respectively [4] Notable Stock Performances - Yunnan Zhiye, a leader in the germanium industry, saw a trading halt with a turnover rate of 12.92% and a total transaction amount of 2.077 billion yuan. The company expects a net profit of 16 million to 23 million yuan for the mid-year report, representing a year-on-year increase of 273% to 348% [5] - Ruizhi Pharmaceutical, focused on CRO and ADC services, also experienced a trading halt with a turnover rate of 24.95% and a total transaction amount of 1.534 billion yuan. The company anticipates a net profit of 170 million to 210 million yuan for the mid-year report, reflecting a year-on-year growth of 94.49% to 140.25% [7] - Xining Special Steel and Tibet Tianlu both achieved trading halts, with turnover rates of 37.99% and 30.68% respectively, indicating strong market interest [13] Trading Dynamics - The trading dynamics showed significant activity from retail investors, with notable net purchases in stocks like Beiyang Changlong and Yunnan Zhiye, while there were substantial net sales in stocks like Boyun New Materials and Shanghai Film [16][19]

Group 1 - The three major domestic airlines in China, Air China, China Southern Airlines, and China Eastern Airlines, have announced their support for the "Civil Aviation Version 12306" direct sales platform for ticket purchases, ensuring passenger rights [3] - The airlines have initiated direct sales of tickets through the "Hanglv Zongheng" platform, which offers transparent pricing, no bundled sales, and aligns with airline rules, ensuring information security [3] - The tickets sold on the "Hanglv Zongheng" platform are directly sourced from the airlines, unlike traditional OTAs such as Ctrip and Qunar, which rely on multiple ticket agents [3] Group 2 - The National Childcare Subsidy Implementation Plan was announced, providing an annual subsidy of 3,600 yuan for each child, regardless of whether they are the first, second, or third child, starting from January 1, 2025 [4] - Following the announcement, stocks related to the three-child policy, such as Beiyinmei and Sunshine Dairy, saw significant increases, with some stocks hitting the daily limit [4] Group 3 - The International Monetary Fund (IMF) has raised its forecast for China's economic growth this year by 0.8 percentage points to 4.8%, reflecting stronger-than-expected economic activity in the first half of the year [8] - The IMF also adjusted global economic growth forecasts for this year and next, indicating a resilient but fragile global economic outlook [8] Group 4 - Standard Chartered Group has signed a strategic cooperation memorandum with Alibaba Group to accelerate the integration of financial services and artificial intelligence technology [21] - The partnership aims to leverage Alibaba Cloud's AI capabilities to enhance financial services [21] Group 5 - Heng Rui Pharmaceutical has entered into a cooperation agreement with GlaxoSmithKline (GSK) to jointly develop up to 12 innovative drugs, with GSK paying an upfront fee of $500 million and potential milestone payments of up to $12 billion [18] - This collaboration highlights the increasing trend of multinational pharmaceutical companies partnering with domestic firms at earlier stages of drug development [18] Group 6 - The 2025 Fortune Global 500 list revealed that 130 Chinese companies made the list, with a total revenue of approximately $10.7 trillion, a decrease of about 3% compared to the previous year [11] - The average revenue of Chinese companies on the list was approximately $82 billion, lower than that of U.S. companies, which averaged $105.8 billion [11]

今日关注 1、国务院新闻办公室定于2025年7月30日（星期三）下午2时举行新闻发布会，请国家卫生健康委副主 任郭燕红和财政部、国家医保局、全国总工会有关负责人介绍育儿补贴制度及生育支持措施有关情况， 并答记者问。 2、国务院新闻办公室定于2025年7月30日（星期三）上午10时举行"高质量完成'十四五'规划"系列主题 新闻发布会，公安部副部长、国家移民管理局局长王志忠介绍"十四五"时期中国移民管理工作发展成 就，并答记者问。 宏观经济 1、据央视新闻，当地时间7月28日至29日，中美经贸会谈在瑞典斯德哥尔摩举行。根据会谈共识，双方 将继续推动已暂停的美方对等关税24%部分以及中方反制措施如期展期90天。 2、中央网信办发布通知，决定自7月24日起，在全国范围内启动为期2个月的"清朗·整治'自媒体'发布不 实信息"专项行动，重点整治恶意蹭炒误导公众、多种手段歪曲事实等问题。 4、财政部披露，1-6月，国有企业营业总收入40.745万亿元，同比下降0.2%；利润总额2.18万亿元，同 比下降3.1%。6月末，国有企业资产负债率65.2%，同比上升0.3个百分点。 5、中国光伏行业协会发布澄清公告称，近日有部分自 ...